Glycosylation pattern (specifically low fucosylation), low aggregate content ( 98%).
The drug substance was formulated in 20 mM Histidine, 5% Sucrose, 0.02% Polysorbate 80, pH 6.0. Note: Polysorbate 80 was selected over PS20 due to lower hydrolysis risk observed in accelerated stability studies (40°C for 1 month).
A two-stage depth filtration system was selected. The primary coarse filter captured whole cells and large fragments, while the secondary fine filter trapped sub-micron colloidal particles and nucleic acids.
: It provides a framework for defining a Quality Target Product Profile (QTPP) and identifying Critical Quality Attributes (CQAs) like aggregation, galactosylation, and host cell proteins (HCP).
The bioprocess pipeline for mAb A begins with the . The QTPP outlines the clinical performance goals, dosage requirements, and safety standards for the drug. A Mab A Case Study In Bioprocess Development
The top 24 clones were evaluated in automated miniature bioreactors. Clone 14-B7 was selected based on its high specific growth rate ( ) and low lactate accumulation profile. Media and Feed Optimization
The first step in the bioprocess development of A Mab was the creation of a stable and productive cell line. A Mab was produced in a Chinese Hamster Ovary (CHO) cell line, which is a commonly used host for the production of therapeutic proteins. The CHO cell line was transfected with a plasmid containing the gene encoding A Mab, and a clone with high productivity and stability was selected.
), resulting in a final harvest titer of 4.5 g/L over a 14-day culture duration. 2. Harvest and Clarification: The Bridge to Downstream
user wants a detailed case study article on bioprocess development for a monoclonal antibody (mAb). I need to search for relevant information. I'll follow the search plan as outlined. search results have provided a good number of potential case studies and articles. I need to select the most relevant ones to open and gather detailed information for the article. I will open a selection of results that seem promising, covering upstream, downstream, scale-up, regulatory, economic, and biosimilar aspects. search results have provided a variety of case studies and articles covering upstream, downstream, scale-up, regulatory, economic, and biosimilar aspects of mAb bioprocess development. I will now structure the article, drawing on these sources to illustrate key stages with concrete examples. The article will be organized with an introduction, sections for upstream, downstream, scale-up, regulatory considerations, economic evaluation, and a conclusion. I will cite relevant sources for each section. Laboratory to Patient: A Case Study Approach to Mastering mAb Bioprocess Development A two-stage depth filtration system was selected
Modern CLD processes are rapid and high-throughput, leveraging automation to screen thousands of clones. A robust platform process can accelerate this stage, but it is not without risks; the chosen clone's stability and productivity must be verified early to avoid failures later in scale-up.
The cell line development process involved several rounds of cloning and screening to identify a cell line with the desired characteristics, including:
Commercially available ELISA kits quantified residual HCP (
Led by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), the N-mAb project brought together over 60 industry and government stakeholders to create a shared vocabulary and framework for a fully integrated continuous bioprocess for a hypothetical monoclonal antibody. This study explores crucial elements that are unique to continuous manufacturing, such as developing control strategies across an end-to-end process and managing deviations in real-time. The bioprocess pipeline for mAb A begins with the
Should we add a section focused on protocols? Share public link
The journey starts by engineering the factory. A gene encoding the desired antibody is transfected into a stable host cell line, most commonly CHO cells, which are favored for their ability to perform human-like post-translational modifications and grow robustly in suspension culture. The goal of is to isolate a single, high-producing, and stable clone that can consistently deliver the required quantity and quality of the mAb.
The strategic use of platform technologies coupled with targeted, data-driven optimization allowed this mAb to transition smoothly from an early-stage candidate to a commercially viable manufacturing process.
For process engineers, A Mab is a textbook example: rigorous science, meticulous data, and adaptive problem-solving. Whether you are developing your first mAb or your tenth, this case study reminds us that the process is the product.